National Comprehensive Cancer Network

About NCCN

NCCN Flash UpdatesTM: NCCN Guidelines® & NCCN Compendium® Updated

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Myeloid Growth Factors. These NCCN Guidelines are currently available as Version 1.2015.

  • Therapeutic Use of Colony-Stimulating Factors (CSFs) for Febrile Neutropenia (MGF-3)
    • Footnote “n” has been revised: “See Discussion for further details. There are no data on pegfilgrastim in the therapeutic setting. Tbo-filgrastim and pegfilgrastim have only been studied for prophylactic use. Filgrastim, filgrastim-sndz, or sargramostim should may be used therapeutically with initial dosing as outlined in Myeloid Growth Factors for Prophylaxis of Febrile Neutropenia and Maintenance of Scheduled Dose Delivery (MGF-E) and discontinued at time of neutrophil recovery.”
  • The lists of examples of disease settings and chemotherapy regimens with a high/intermediate risk for febrile neutropenia have been updated along with the corresponding references. (MGF-A)
  • Myeloid Growth Factors for Prophylaxis of Febrile Neutropenia (MGF-E)
    • Filgrastim-sndz has been added as an option with a category 1 recommendation.
    • Footnote “c” has been added: "An FDA-approved delivery device is available that can be applied the same day as chemotherapy and set to deliver the full dose of pegfilgrastim the following day. This may be an option for patients who cannot return to the clinic for next-day administration of pegfilgrastim."
  • Myeloid Growth Factors in Mobilization and Post Stem Cell Transplant (MGF-F)
    • Filgrastim-sndz has been added as an option where filgrastim is recommended for mobilization of hematopoietic progenitor cells in autologous setting, in combination with plerixafor, for mobilization of allogenic donors (category 2B), for supportive care, and for mobilization in combination with GM-CSF for post autologous transplant and delayed hematopoietic recovery.
  • The Discussion section has been updated to reflect the changes in the algorithm. (MS-1)

For the complete updated versions of the NCCN Guidelines, the NCCN Compendium®, and the NCCN Chemotherapy Order Templates (NCCN Templates®), please visit NCCN.org.

To access the NCCN Biomarkers Compendium®, please visit NCCN.org/biomarkers.

To view the NCCN Guidelines for Patients®, please visit NCCN.org/patients.

Free NCCN Guidelines apps iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps

 

About NCCN Flash Updates™ 

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium, and other NCCN Content. 

Subscribe to NCCN Flash Updates™ 

 

National Comprehensive Cancer Network® (NCCN®)

275 Commerce Drive, Suite 300

Fort Washington, PA 19034

Telephone: +1 215.690.0300 Fax: +1 215.690.0280 

Access information on permissions and licensing of NCCN Content  

© 2015 National Comprehensive Cancer Network. All Rights Reserved.